VasoMedical to Showcase Proprietary Products at ESC Congress 2014 in Barcelona, Spain

WESTBURY, N.Y. – July 28, 2014VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices including EECP® Therapy systems, the gold standard of ECP therapy, and patient monitoring products, announced today that that it will exhibit at the 2014 European Society of Cardiology (ESC) Congress from August 30 to September 3, 2014 in Barcelona, Spain.

The European Society of Cardiology Congress is the largest cardiology event in the world, with over 30,000 participants every year, 70% of which are cardiologists from 146 countries. The Congress attendees includes fellows and members of the ESC and the other 56 European national societies, the American College of Cardiology (ACC) in the United States, as well as members of other related organization of healthcare professionals worldwide.

VasoMedical's exhibit will be located in Booth #F600, at the Fira Gran Via Conference Centre.

Joined by colleagues from the BIOX Instruments Co. Ltd., Wuxi, China, VasoMedical's international sales and marketing group will exhibit and demonstrate the expanding product line, including the Lumenair EECP Therapy system, BIOX™ ambulatory monitoring systems and analysis software. This year, the Company will also highlight its new MobiCareTM Wireless Patient Monitoring technology, featuring its flexibility to provide wireless vital signs monitoring capabilities for a variety of clinical situations.

“We look forward to participating at this year's ESC Congress and showcasing our advanced technologies. This well attended international meeting allows us the opportunity to present our products on the world's largest cardiology stage and increase exposure for the Company to tens of thousands of medical professionals,” stated Larry Liebman, Vice President of Sales & Marketing at VasoMedical Solutions, Inc.

“This is the first ESC Congress since last year's addition of EECP therapy to the updated 2013 European Society of Cardiology (ESC) Guidelines on the Management of Stable Coronary Artery Disease (SCAD), and therefore we anticipate an increase in the level of interest for EECP Therapy from the European healthcare market as well as other markets around the world. With a IIa Level of Recommendation in the guidelines, the ESC has recommended that EECP Therapy should be considered as a treatment option for patients suffering from the symptoms of stable ischemic heart disease.”

“In addition to EECP Therapy, we will also be focused on creating greater awareness of MobiCareTM, our new wireless monitoring technology along with our high quality, easy to use, advanced ambulatory monitoring solutions,” concluded Mr. Liebman.

About VasoMedical

VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through four wholly owned subsidiaries: VasoMedical Solutions, Inc., VasoMedical Global Corp., Vaso Diagnostics, Inc. d.b.a. VasoHealthcare, and VasoHealthcare IT Corp. VasoMedical Solutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments; and VasoHealthcare IT is a national value added reseller of GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support.. Additional information is available on the Company's website at

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreements; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250 /

Media Contacts:
Samantha Wolf / Andrew Herweg
KCSA Strategic Communications
212-896-1220 / 212-896-1273 /

Home | Back to News

©2017 Vaso Corporation